X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Ipsen acquired exclusive commercialization rights for the current and potential future Onivyde, a unique encapsulation formulation of irinotecan in a long-circulating liposomal, as a first-line treatment of metastatic adenocarcinoma on the pancreas in the US.
Lead Product(s): Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: Onivyde
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ipsen
Deal Size: $1,025.0 million Upfront Cash: $575.0 million
Deal Type: Acquisition March 27, 2024
Details:
Astellas' Vyloy (zolbetuximab), a CLDN 18.2 inhibitor has been approved in combination with chemotherapy for patients with HER2-negative, CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer.
Lead Product(s): Zolbetuximab,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: VYLOY
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
AbilityPharma to obtain financing for the clinical development of ABTL0812 in combination with folfirinox. It is being evaluated in Phase I/II clinical trial studies for the treatment of Metastatic Pancreatic Cancer.
Lead Product(s): ABTL0812,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: ABTL0812
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CTI Life Sciences
Deal Size: $7.6 million Upfront Cash: Undisclosed
Deal Type: Financing March 11, 2024
Details:
Oncotelic lead product candidate, OT-101 is a TGF beta-2 inhibitor in combination with folfirinox. It is currently being evaluated in the Phase 2/3 clinical trial studies with patients for the treatment of Pancreatic Ductal Adenocarcinoma.
Lead Product(s): OT-101,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
Onivyde (irinotecan), liposomal injection is a small molecule drug that blocks an enzyme called topoisomerase I. It is being developed for the treatment of metastatic pancreatic adenocarcinoma.
Lead Product(s): Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: Onivyde
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
AMP945 (narmafotinib) is a novel focal adhesion kinase (FAK) inhibitor. It is being evaluated in precliical studies for the treatment of patients with pancreatic cancer.
Lead Product(s): AMP945,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: AMP945
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Details:
Imfinzi (durvalumab) is a PD-L1 Inhibitor antibody drug candidate, which is currently being evaluated in combination with fluorouracil & leucovorin for the treatment of resectable gastric and gastroesophageal junction cancer.
Lead Product(s): Durvalumab,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
Natrunix (vilamakitug) is a unique kind of drug, an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor, and is investigated in combination with chemotherapy for treating pancreatic cancer.
Lead Product(s): Vilamakitug,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area: Oncology Product Name: Natrunix
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
Onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Onvansertib,Bevacizumab,Calcium Folinate
Therapeutic Area: Oncology Product Name: PCM-075
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2023
Details:
Under the Agreement, Allarity will support FivepHusion’s future clinical development of Deflexifol (5-fluorouracil) for the treatment of solid tumors by using certain of Allarity’s drug-specific DRP® companion diagnostics, including its validated DRP®-5FU companion diagnostic.
Lead Product(s): Fluorouracil,Calcium Folinate,Oxaliplatin
Therapeutic Area: Oncology Product Name: Deflexifol
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Allarity Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 31, 2023
Details:
Onivyde (irinotecan) is a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. By blocking the enzyme, which is investigated for treatment of pancreatic ductal adenocarcinoma.
Lead Product(s): Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: Onivyde
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023
Details:
AMP945 (narmafotinib) is an orally bioavailable small molecule with a best-in-class profile. Amplia’s highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer.
Lead Product(s): AMP945,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: AMP945
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2023
Details:
The collaboration is for strategically and optimally progress development and commercialization of FivepHusion's enhanced chemotherapeutic formulation Deflexifol, an anti-cancer drug reformulation combining 5-fluorouracil and its biomodulator leucovorin, in global markets.
Lead Product(s): Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: Deflexifol
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Syneos Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 26, 2023
Details:
PCM-075 (onvansertib) is a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS/NRAS-mutated cancers.
Lead Product(s): Onvansertib,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area: Oncology Product Name: PCM-075
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
IMAB362 (zolbetuximab) is an investigational, first-in-class chimeric IgG1 mAb that targets and binds to CLDN18.2 present on the cancer cell surface of gastric epithelial cells. It induces cancer cell death by activating ADCC and CDC immune system.
Lead Product(s): Zolbetuximab,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: IMAB362
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2023
Details:
ADC-1013 (Mitazalimab) is an agonistic/stimulatory antibody that targets and activates CD40 (receptor on the dendritic cells of the immune system), enabling dendritic cells to stimulate the immune response’s weapons more effectively to attack the cancer selectively.
Lead Product(s): Mitazalimab,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2023
Details:
IMAB362 (zolbetuximab) is an investigational first-in-class mAB targeting Claudin 18.2 (CLDN18.2), for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Lead Product(s): Zolbetuximab,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: IMAB362
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
The antibody CAN04 (nadunolimab) binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1α and IL-1β signaling. It can counteract contribution of IL-1 system to immune suppressive tumor microenvironment and development of resistance to chemotherapy.
Lead Product(s): Nadunolimab,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: CAN04
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022
Details:
CYAD-101 is an investigational, non-gene edited allogeneic CAR T engineered to co-express chimeric antigen receptor based on NKG2D, that binds to eight stress-induced ligands expressed by a broad range of tumor cells and the novel inhibitory peptide TIM.
Lead Product(s): CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: CYAD-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
Proceeds will support the development of lead candidate RGX-202-01 (“RGX-202”), an oral small molecule inhibitor of SLC6a8 to treat RAS mutant advanced colorectal cancer and RGX-104, an oral small molecule activator of LXR/APOE to treat lung and endometrial cancer.
Lead Product(s): RGX-202-01,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area: Oncology Product Name: RGX-202-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sands Capital
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing July 11, 2022
Details:
Under the terms of the agreement, GenFleet will fully fund, design and execute a randomized Phase 2b clinical trial for BL-8040 (motixafortide) that will enroll approximately 200 first-line metastatic PDAC patients in China.
Lead Product(s): Motixafortide,Pembrolizumab,Calcium Folinate
Therapeutic Area: Oncology Product Name: BL-8040
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: GenFleet Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 28, 2022
Details:
RGX-202-01 is an oral, potential first-in-class small molecule inhibitor of SLC6a8, a creatine transporter that drives colorectal cancer and certain other cancers’ progression.
Lead Product(s): RGX-202-01,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area: Oncology Product Name: RGX-202-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
CEND-1 is an investigational drug that modifies the tumor microenvironment. It is targeted to tumor vasculature by its affinity for alpha-v integrins that are selectively expressed in tumor, but not healthy tissue vasculature.
Lead Product(s): CEND-1,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: CEND-1
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Lisata Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
The results of trial showed that mFOLFOX6 + Vectibix (Panitumumab) combination provides a statistically significant improvement in OS over mFOLFOX6 + bevacizumab combination in patients with a left-sided primary tumor or regardless of tumor locations.
Lead Product(s): Panitumumab,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: Vectibix
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2022
Details:
RGX-202-01 is an oral, potential first-in-class small molecule inhibitor of SLC6a8, a creatine transporter that drives colorectal cancer and certain other cancers’ progression.
Lead Product(s): RGX-202-01,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area: Oncology Product Name: RGX-202-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
CEND-1 is a cyclic peptide that, once bound to these integrins, is cleaved by proteases expressed in tumors to release a peptide fragment, called a CendR fragment, which binds to a second receptor, called neuropilin-1, to activate a novel uptake pathway.
Lead Product(s): CEND-1,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: CEND-1
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Lisata Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
RGX-202-01, oral small-molecule inhibitor of SLC6A8 that induces apoptosis of colorectal cancer cell, is being tested in combination with the FOLFIRI and bevacizumab in a Phase 1b clinical trial for 2nd line treatment of patients with cancer whose tumors express CKB.
Lead Product(s): RGX-202-01,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area: Oncology Product Name: RGX-202-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
Ampligen (rintatolimod) has demonstrated in clinic potential for standalone efficacy in a number of solid tumors, it also has shown success in increasing survival rates and efficacy in treatment of animal tumors when used in combination with checkpoint blockade therapies.
Lead Product(s): Rintatolimod,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2022
Details:
Results showed Reolysin (pelareorep) treatment led to the activation of NK cells, in patient samples and in vitro, which are known to directly kill cancer cells while stimulating adaptive anti-tumor immunity.
Lead Product(s): Pelareorep,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: Reolysin
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
Company announced clinical hold on CYAD-101-002 Phase 1b trial for CYAD-101, TCR Inhibitory Molecule based allogeneic NKG2D CAR T cell investigational therapy for treatment of advanced mCRC, due to insufficient information to assess risk to study subjects.
Lead Product(s): CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: CYAD-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
NUC-3373 (fosifloxuridine nafalbenamide), a new chemical entity derived from the nucleoside analog 5-fluorouracil, continues rapid development with multiple data readouts and dosing of first patients in Phase 3 colorectal cancer study.
Lead Product(s): Fosifloxuridine Nafalbenamide,Calcium Folinate
Therapeutic Area: Oncology Product Name: NUC-3373
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
The trial is evaluating TCR Inhibitory Molecule-based allogeneic NKG2D CAR T cell investigational therapy CYAD-101 administered concurrently with FOLFOX chemotherapy, followed by MSD’s anti-PD-1 therapy, KEYTRUDA®, in patients with refractory metastatic colorectal cancer.
Lead Product(s): CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: CYAD-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2022
Details:
The sponsored research collaboration will support the UPENN study, a part of Alligator’s OPTIMIZE-1 clinical trial, multi-center phase 1B/I I trial assessing the clinical efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic cancer.
Lead Product(s): Mitazalimab,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: University of Pennsylvania
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 19, 2022
Details:
ADC-1013 (mitazalimab), a CD40 agonist reported no adverse event at dosed of 450 µg/kg cohort in combination with mFOLFIRINOX for treatment of pancreatic ductal adenocarcinoma in OPTIMIZE-1 Phase Ib/II trial.
Lead Product(s): Mitazalimab,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2022
Details:
The Company intends to use net proceeds from the private placement to fund research and development expenses, including the clinical development of its allogeneic CAR T candidates CYAD-101 and CYAD-211, to advance the current pipeline of preclinical CAR T candidates.
Lead Product(s): CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: CYAD-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Fortress Investment Group
Deal Size: $32.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 03, 2021
Details:
The positive opinion is based on results from pivotal Phase 3 CheckMate -649 trial, in which first-line treatment with Opdivo plus FOLFOX or capecitabine and oxaliplatin (CapeOX) to treat HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction.
Lead Product(s): Nivolumab,Calcium Folinate,Oxaliplatin
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2021
Details:
The webinar will include presentation of new data from Cardiff Oncology's Phase 1b/2 clinical trial evaluating onvansertib in combination with standard-of-care FOLFIRI/bevacizumab in KRAS-mutated mCRC.
Lead Product(s): Onvansertib,Bevacizumab,Calcium Folinate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2021
Details:
This third clinical study, named CAPAFOUR, aims to investigate CAN04 in combination with one of the two most commonly used first line chemotherapy regimens in metastatic PDAC, FOLFIRINOX.
Lead Product(s): Nadunolimab,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: CAN04
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2021
Details:
The incidence of corneal adverse events was higher in the bemarituzumab plus chemotherapy arm versus the chemotherapy arm (all grade AEs 67.1% versus 10.4%), with dry eye reported as the most common corneal event (26.3%).
Lead Product(s): Bemarituzumab,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: FPA144
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2021
Details:
Covering Padcev, Xtandi, Xospata and IMAB362, the abstracts underscore the company’s commitment to advancing treatment options for difficult-to-treat cancers, including bladder, prostate and gastric/gastroesophageal junction (GEJ) cancers, as well as acute myeloid leukemia.
Lead Product(s): Zolbetuximab,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: IMAB362
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2021
Details:
Designation is supported by results from the phase 2 FIGHT trial. The FIGHT trial evaluated bemarituzumab plus chemotherapy (mFOLFOX6) versus chemotherapy alone in patients with FGFR2b+, non-HER2 positive frontline advanced gastric or GEJ cancer.
Lead Product(s): Bemarituzumab,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: FPA144
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2021
Details:
Five Prime fits squarely within Amgen's leading oncology portfolio and includes bemarituzumab, a Phase 3 trial-ready, first-in-class program for gastric cancer, the third leading cause of cancer mortality worldwide.
Lead Product(s): Bemarituzumab,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: FPA144
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $1,900.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 16, 2021
Details:
In the trial of this patient population, Opdivo plus chemotherapy demonstrated superior overall survival (OS) compared to chemotherapy alone, both in all randomized patients, as well as in patients with PD-L1 combined positive score.
Lead Product(s): Nivolumab,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2021
Details:
Alymsys (bevacizumab-maly) is a vascular endothelial growth factor inhibitor for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.
Lead Product(s): Bevacizumab-maly,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: Alymsys
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Zentiva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 09, 2021
Details:
Clinical trial application has been submitted for a study which investigates CAN04 in combination with FOLFIRINOX treatment, one of the two most commonly used first line chemotherapies in PDAC.
Lead Product(s): CAN04,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: CAN04
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2021
Details:
Five Prime's lead asset, bemarituzumab, is a first-in-class, Phase 3 ready anti-FGFR2b antibody with positive data from a randomized, placebo-controlled Phase 2 study in frontline advanced gastric or gastroesophageal junction (GEJ) cancer.
Lead Product(s): Bemarituzumab,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: FPA144
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $1,900.0 million Upfront Cash: $1,900.0 million
Deal Type: Acquisition March 04, 2021
Details:
Trial will evaluate the safety and efficacy of onvansertib in combination with standard-of-care for second-line treatment of patients with metastatic PDAC who have failed first line treatment with a gemcitabine-based chemotherapy regimen.
Lead Product(s): Onvansertib,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2021
Details:
The filing was based on results from the pivotal Phase 3 CheckMate -649 trial. Opdivo plus leucovorin, 5-fluorouracil and oxaliplatin or capecitabine and oxaliplatin led to a statistically significant improvement in overall survival (OS) and progression-free survival (PFS).
Lead Product(s): Nivolumab,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2021
Details:
The recommended dose of 1×109 CYAD-101 cells per infusion will be further evaluated in the expansion cohort of the alloSHRINK trial concurrently with FOLFIRI chemotherapy.
Lead Product(s): CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: CYAD-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2021
Details:
10 patient out of 37 case studies highlighted NUC-3373’s ability to stabilize disease and achieve prolonged durations of progression-free survival. Many patients achieved longer progression-free survival on NUC-3373 than they had on their prior line of therapy.
Lead Product(s): Fosifloxuridine Nafalbenamide,Calcium Folinate
Therapeutic Area: Oncology Product Name: NUC-3373
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
